Dechra Pharmaceuticals (LON: DPH) has announced that Paul Sandland, acting Chief Financial Officer since April this year, has been appointed as an Executive Director and permanent Chief Financial Officer of the Company with immediate effect.
Paul qualified as a Chartered Certified Accountant with KPMG in 2005 and joined Dechra in 2010 as Group Financial Controller. Between 2012 and 2013 Paul was Acting CFO prior to becoming the Group’s Dechra Veterinary Products EU finance director, a position he held until April this year.
Commenting on the appointment Tony Rice, Chairman, said:
“I am delighted to confirm Paul’s appointment as Dechra’s permanent CFO. Paul has proven to be an excellent acting CFO and, over a much longer period, has clearly demonstrated a strong practical understanding of all parts of the Group and its needs, as well as an independence of mind and strong technical, strategic and commercial skills. The Company followed a rigorous process before appointing Paul. He has been a core part of the Dechra leadership team over the last ten years.”
Paul Sandland, Dechra Pharmaceuticals Chief Financial Officer added:
“I am delighted to take on the CFO role on a permanent basis. Dechra is a wonderful, well invested Company with global brands and significant growth opportunities ahead of it. Whilst I have been privileged to be part of the development of Dechra over the last ten years, I am confident that Dechra continues to have enormous potential and, working alongside the talented pool of people we have around the business at all levels, I look forward to helping unlock that potential.”
Paul Sandland currently has a beneficial interest in the Company totalling 5,069 shares which represents 0.005% of the current issued share capital.
